Citadel Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-20,300
| Closed | -$100K | – | 15461 |
|
|
2021
Q3 | $100K | Buy |
20,300
+7,900
| +64% | +$38.4K | ﹤0.01% | 12876 |
|
|
2021
Q2 | $65K | Sell |
12,400
-22,300
| -64% | -$115K | ﹤0.01% | 13213 |
|
|
2021
Q1 | $167K | Buy |
34,700
+21,900
| +171% | +$114K | ﹤0.01% | 11934 |
|
|
2020
Q4 | $55K | Buy |
+12,800
| New | +$54.8K | ﹤0.01% | 10538 |
|
|
2020
Q3 | – | Sell |
-10,800
| Closed | -$28K | – | 11036 |
|
|
2020
Q2 | $28K | Buy |
+10,800
| New | +$31.7K | ﹤0.01% | 9481 |
|
|
2019
Q4 | – | Sell |
-13,000
| Closed | -$66K | – | 10043 |
|
|
2019
Q3 | $66K | Buy |
+13,000
| New | +$80.3K | ﹤0.01% | 8636 |
|
|
2019
Q1 | – | Sell |
-36,000
| Closed | -$307K | – | 10122 |
|
|
2018
Q4 | $307K | Sell |
36,000
-1,600
| -4% | -$20.8K | ﹤0.01% | 7222 |
|
|
2018
Q3 | $753K | Buy |
37,600
+13,100
| +53% | +$308K | ﹤0.01% | 6028 |
|
|
2018
Q2 | $633K | Buy |
24,500
+8,600
| +54% | +$238K | ﹤0.01% | 5989 |
|
|
2018
Q1 | $380K | Sell |
15,900
-7,500
| -32% | -$236K | ﹤0.01% | 6354 |
|
|
2017
Q4 | $793K | Buy |
23,400
+13,700
| +141% | +$383K | ﹤0.01% | 4989 |
|
|
2017
Q3 | $205K | Buy |
+9,700
| New | +$178K | ﹤0.01% | 6661 |
|
|
2016
Q1 | – | Sell |
-3,800
| Closed | -$108K | – | 8411 |
|
|
2015
Q4 | $108K | Buy |
+3,800
| New | +$64K | ﹤0.01% | 6601 |
|
Citadel Advisors's ADMS Position: Q4 2021 in Review
Citadel Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 27,776 shares — an estimated $136K sold.
Citadel Advisors first reported a position in ADMS in Q3 2014 and held it in 23 quarters. The position peaked at $16.5M in Q3 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Citadel Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 27,776 Adamas Pharmaceuticals shares in Q4 2021, an estimated $136K.
- Citadel Advisors first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 23 quarters.
- Citadel Advisors's Adamas Pharmaceuticals position peaked at $16.5M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.